FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:1235-1237 October 17, 1996 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Charache, S. Related Article by Hubbard, R.

To the Editor: In their discussion of pitfalls of genetic testing (May 2 issue)¹ Hubbard and Lewontin seriously misrepresent several issues with regard to predictive genetic testing for mutations in the BRCA1 gene, and specifically testing for the 185delAG mutation in Jews. Their view that "DNA tests cannot usually help clinicians or benefit patients" is inconsistent with the view of many experts in medical genetics. In the same issue of the Journal, Haber et al. state that the 185delAG mutation is likely to be "a fully penetrant allele" and that the lifetime risk of breast cancer in 185delAG carriers is . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.